Figure 4
Figure 4. Analysis of engraftment and differentiation of HSCs and proT2-cells in the thymus of immunodeficient mice. (A) Flow cytometric analysis of CD45 vs HLA-A2, and CD4 and CD8 on CD45+HLA-A2+–gated (HSC-derived) and CD45+HLA-A2− –gated (proT2-derived) cells in the thymus at 6 weeks after intrahepatic injection of NSG mice receiving either HSCs, HSCs with proT2-cells, or proT2-cells. (B) Percentage of human CD45+HLA-A2+ HSC-derived engraftment at 3 to 6 weeks and 9 to 12 weeks after intrahepatic injection of neonatal mice receiving either HSCs (white) or HSCs with proT2 cells (black). Table 2 shows the number of mice analyzed. The results shown are representative of at least 3 independent experiments. *P < .05.

Analysis of engraftment and differentiation of HSCs and proT2-cells in the thymus of immunodeficient mice. (A) Flow cytometric analysis of CD45 vs HLA-A2, and CD4 and CD8 on CD45+HLA-A2+–gated (HSC-derived) and CD45+HLA-A2 –gated (proT2-derived) cells in the thymus at 6 weeks after intrahepatic injection of NSG mice receiving either HSCs, HSCs with proT2-cells, or proT2-cells. (B) Percentage of human CD45+HLA-A2+ HSC-derived engraftment at 3 to 6 weeks and 9 to 12 weeks after intrahepatic injection of neonatal mice receiving either HSCs (white) or HSCs with proT2 cells (black). Table 2 shows the number of mice analyzed. The results shown are representative of at least 3 independent experiments. *P < .05.

Close Modal

or Create an Account

Close Modal
Close Modal